Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
The FDA has approved the combination of talazoparib (Talzenna) and enzalutamide (Erleada) for adults with HRR gene–mutated metastatic prostate cancer that is androgen pathway modulation–naive or –sensitive. The approval was backed by the phase 3 TALAPRO-3 trial, which showed the combo nearly halved the risk of radiographic progression or death compared to enzalutamide alone. This marks a meaningful new option for a genetically defined subset of prostate cancer patients.
The FDA has approved talazoparib (Talzenna) combined with enzalutamide (Erleada) for adult patients with metastatic androgen pathway modulation–naive or –sensitive (mAPM/S) prostate cancer harboring homologous recombination repair (HRR) gene mutations, as confirmed by an FDA-authorized companion diagnostic test. The approval is supported by data from the randomized, double-blind, placebo-controlled phase 3 TALAPRO-3 trial.
In the trial, the talazoparib-enzalutamide combo delivered a statistically significant improvement in radiographic progression-free survival (rPFS) over placebo plus enzalutamide, with median rPFS not yet reached in the experimental arm versus 45.8 months in the control arm. The 36-month OS rates also trended favorably at 77.8% vs. 71.6%, though OS data remain immature. The recommended dose is talazoparib 0.5 mg orally once daily alongside enzalutamide.
By the Numbers:
Why it matters: This approval expands targeted treatment options for a genomically defined subset of metastatic prostate cancer patients, reinforcing the role of HRR mutation testing in guiding therapy decisions and offering a new combination option earlier in the disease course.
